Answers are grounded in this paper and cite their sources.
In this article we will review the role of long acting beta2-adrenoreceptor agonists and long-acting muscarinic agents in the management of airflow obstruction. We will then focus our attention on indacaterol, one of the new once daily inhaled beta2-adrenoreceptor agonists. Pharmacologically this drug is a nearly full beta2-agonist without loss of efficacy after prolonged administration. We will also discuss its dosing, safety and tolerability.
No takes yet. Share an insight, caveat, or question.
Roig et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: